Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation | |
---|---|---|
D007248 | Infertility, Male NIH | 1.00 |
D007246 | Infertility NIH | 0.38 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0003251 | Male infertility HPO | 1.00 |
HP:0000789 | Infertility HPO | 0.38 |
Navigate: Correlations HPO
There is one clinical trial.
Study rationale 1. An increasing proportion of the worldwide population is being infected with COVID-19. 2. There are ongoing and currently unanswered safety concerns about the effects of COVID-19 on reproductive health. 3. It will be immensely reassuring to rapidly report that COVID-19 has no detectable effects on male endocrine or sperm function. Conversely, if COVID-19 does impair male reproductive health, appropriate screening can be performed in couples trying to conceive, and further research can be undertaken. 4. The proposed study will be simple, rapid, and authoritative for the UK and worldwide.
Description: Sperm concentration (x10^6/ml) between case and control group.
Measure: Semen parameters Time: 3 visits (up to 75 days apart)Description: Sperm Motility (%) between case and control group.
Measure: Sperm Parameters Time: 3 visits (up to 75 days apart)Description: Sperm normal morphology (%) between case and control group.
Measure: Sperm Parameters Time: 3 visits (up to 75 days apart)Description: Testosterone (nmol/L) between case and control group.
Measure: Hormones measurement Time: 3 visits (up to 75 days apart)Description: Follicle Stimulating Hormone(IU/L) between case and control group.
Measure: Hormones measurement Time: 3 visits (up to 75 days apart)Description: Luteinising hormone(IU/L) between case and control group.
Measure: Hormones measurement Time: 3 visits (up to 75 days apart)Description: Compare seminal reactive oxidative species (RLU/second/10^6sperm) between case and control group.
Measure: Seminal Reactive oxygen species Time: 3 visits (up to 75 days apart)Description: Compare Sperm DNA fragmentation rate (%) between case and control group.
Measure: Sperm DNA fragmentation rate Time: 3 visits (up to 75 days apart)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports